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Personalized cancer medicine is based on increased knowledge of the cancer mutation repertoire
and availability of agents that target altered genes or pathways. Given advances in cancer genetics,
technology, and therapeutics development, the timing is right to develop a clinical trial and research
framework to move future clinical decisions from heuristic to evidence-based decisions. Although
the challenges of integrating genomic testing into cancer treatment decisionmaking arewide-rang-
ing and complex, there is a scientific and ethical imperative to realize the benefits of personalized
cancer medicine, given the overwhelming burden of cancer and the unprecedented opportunities
for advancements in outcomes for patients.Introduction
Numerous models have been proposed to explain the complex
nature of cancer at molecular, cellular, and pathological
levels (Hanahan and Weinberg, 2000, 2011). One model that
explains cancer initiation, progression, dissemination, treatment
response, and emergence of drug resistance is based on the
progressive accumulation of mutations throughout the history
of a tumor and its downstream colonies (Figure 1). Though
incomplete, the somatic mutation model does incorporate one
of the most consistent hallmarks of cancer: DNA mutations are
found in all cancers. In addition, specific mutations have been
linked to one or more forms of cancers, and mutant gene prod-
ucts have been associated with biological characteristics of
cancer.
The spectrum of cancer mutations is diverse in terms of type,
number, and functional consequences. Examples include single
base changes that alter protein activity, amplifications, and dele-
tions that modify the abundance of a gene and its products and
alternative splicing or translocations that can create novel
proteins. Mutations are abundant in cancer cells, numbering
between thousands and hundreds of thousands per tumor
(Stratton, 2011; Wong et al., 2011). However, most mutations
in cancer cells do not appear to play a role in cancer progression;
rather, they are indicative of the high mutation rate resulting from
carcinogens and DNA instability (Pleasance et al., 2010a,
2010b). Such mutations have been called ‘‘passengers.’’ A
minority of cancer mutations are thought to be ‘‘drivers,’’ defined
as mutations involved in the development or progression of
a tumor. A subset of these drivers and their component cellular
pathways may be ‘‘actionable,’’ i.e., have significant diagnostic,
prognostic, or therapeutic implications in subsets of cancerpatients and for specific therapies. A subset of mutations may
also be druggable, i.e., targets for therapeutic development.
Given current knowledge on gene function, classifyingmutations
into drivers and passengers—actionable and/or druggable—is
difficult. It is still too early to deduce how many mutations are
active at any given stage of a tumor. Moreover, the constant
accumulation of mutations, with or without exogenous selective
pressures of therapy, implies that tumors evolve to encompass
many subpopulations that have distinct differences in mutation
load within and between patients (Figure 1). Although there is
great diversity in the types and numbers of mutations in human
cancer, our ability to annotate and to assess functional and clin-
ical consequence has expanded remarkably.
DNA sequencing technologies now allow whole-genome,
exome, and transcriptome sequencing at rates that are dramat-
ically faster and cheaper than traditional Sanger-based
methods. Quantifying and cataloguing mutations, transcrip-
tomes, and methylomes for many forms of cancer are underway
in dozens of countries through coordinated projects of the Inter-
national Cancer Genome Consortium (ICGC) (Hudson et al.,
2010). Already, partial cancer genome data sets are available
for several thousands of tumors with protein-altering mutations
affecting more than 7,500 genes inventoried to date (ICGC Data-
set Version 6; http://www.icgc.org). The availability of these
large cancer data sets in the public domain will foster significant
follow-up research by academia and industry and will lead to the
validation of many new driver mutations, drug targets, and clin-
ically useful biomarkers.
A subset of mutations are being branded as ‘‘actionable’’ by
clinicians, based on evidence from clinical studies that the pres-
ence or absence of gene mutations in tumor (and occasionallyCell 148, February 3, 2012 ª2012 Elsevier Inc. 409
Figure 1. Accumulation of Driver Mutations in the History of a Tumor
Exposure to carcinogens, failure of DNA repair, and progressive genetic
instability lead to accumulation of mutations that drive cancer development,
growth, and metastases. Subclones with new mutations may become domi-
nant within metastases or within persistent or recurrent cancer deposits
through selective pressures exerted by cytotoxic or targeted chemotherapies.germline) DNA can be used to inform clinical management
(Table 1). Some examples includeKRASmutations that correlate
with resistance to epidermal growth factor receptor (EGFR)
antibodies in colorectal cancer and BCR-ABL fusion gene prod-
ucts that are pathognomonic of chronic myelogenous leukemia
and can be inhibited by agents such as imatinib. The list of
potential actionable mutations that may impact on treatment
recommendations for predictive or prognostic reasons, or those
with known prognostic or diagnostic implications, is growing.410 Cell 148, February 3, 2012 ª2012 Elsevier Inc.Notwithstanding the historical links between certain actionable
mutations and specific cancer histologies, further exploration
has revealed that specific mutations are often observed across
a range of tumor histologies, albeit at different frequencies.
Figure 2 highlights many genes, including some with known
actionable mutations, which are altered in several common
cancers. One testable hypothesis is that mutations act as
‘‘drivers’’ in most if not all tumors where they are observed.
Moreover, if a mutation is predictive of a drug response in one
form of tumor (for example, BRAF V600E and vemurafenib for
melanoma; Chapman et al., 2011), then theremay be some likeli-
hood that the same drug could affect tumors from other origins
with the same mutation (for example, BRAF V600E and ovarian
cancer; Sieben et al., 2004). It is clear, however, that this hypoth-
esis requires formal testing, as experience to date suggests that
the presence of a specific genetic abnormality may not confer
the same sensitivity to an agent across all cancers, as exempli-
fied by trastuzumab, which has been shown to benefit patients
with HER2-amplified breast and gastric cancer, but not those
with ovarian or endometrial cancer (Bang et al., 2010; Bookman
et al., 2003; Fleming et al., 2010).
If, in fact, the functional consequence of a specific mutation is
similar across different cancers, the clinical implications are
unavoidable. Rather than approaching each patient’s tumor
investigation with an organ-based list of mutation tests, one
could systematically perform a global search for all such ‘‘action-
able’’ mutations in any type of cancer and test targeted thera-
peutics in patients with the specific mutation(s) regardless
of cancer histology. One of the key reasons to test this approach
in the clinical setting now is the need to elucidate further
whether many of the targeted anticancer therapies that are
approved for specific cancer types may benefit patients with
other forms of cancer that share similar genetic profiles and
biologic features.
Framework Requirements for Evaluating the Genetic
Basis for Cancer Treatment
It is important to recognize early that obtaining convincing
evidence to guide future clinical decisions formatching therapies
to mutations affecting unique patients with different tumor types
will require large numbers of patients in meticulously conducted
clinical trials. The goal of these initial trials will be to determine
which mutation profiles correlate with sensitivity or resistance
to specific therapies and whether the mutation profile and treat-
ment outcome is consistent among different cancer histologies.
As opposed to a classical randomized controlled trial in which
a novel therapeutic strategy is assessed against current stan-
dard practice, a genomics-based clinical trial offers the potential
formany different therapeutic options to be selected on the basis
of genomic profiling. Each subgroup of patients harboring
a specificmutation and receiving a targeted therapy (or assigned
to a control group) will represent a minority of patients recruited.
To achieve power to determine whether outcome is improved in
subgroups, genomics-based clinical trials require both large
sample sizes and large treatment effects within the mutation-
defined subgroups. For example, a 1,000 patient genomic
profiling trial could recruit 100 subjects harboring mutations in
a target gene at 10% frequency, allowing a two-armed nested
Table 1. Selected Genetic Markers and Their Application in Cancer Treatment
Genetic Marker Application Drug
BCR-ABL Ph+ CML; Ph+ ALL Imatinib, dasatinib, nilotinib
BCR-ABL/T315I Resistance to anti-BCR-ABL agents Imatinib, dasatinib, nilotinib
BRAF V600E Metastatic melanoma Vemurafenib
BRCA1/2 Metastatic ovarian cancer and breast cancer with BRCA 1/2 mutations Olaparib, veliparib, iniparib
c-Kit Kit (CD117)-positive malignant GIST Imatinib
EGFR Locally advanced, unresectable, or metastatic NSCLC Erlotinib, gefitinib
EGFR T790M Resistance to EGFR tyrosine kinase inhibitors in advanced NSCLC Erlotinib, gefitinib
EML4-ALK ALK kinase inhibitor for metastatic NSCLC with this fusion gene Crizotinib
HER2 amplification HER2-positive breast cancer or metastatic gastric or gastroesophageal
junction adenocarcinoma
Trastuzumab
KRAS Resistance to EGFR antibodies in metastatic colorectal cancer Cetuximab, panitumumab
PML/RAR Acute promyelocytic leukemia ATRA, arsenic trioxide
TPMT Deficiency is associated with increased risk of myelotoxicity Mercaptopurine, azathioprine
UGT1A1 Homozygosity for UGT1A1*28 is associated with risk of toxicity Irinotecan
DPD Deficiency is associated with risk of severe toxicity 5-Fluorouracil
ATRA, all trans retinoic acid; Ph+, Philadelphia-positive chromosome; DPD, dihydropyrimine dehydrogenase; EGFR, epidermal growth factor
receptor; EML4-ALK, echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase; HER2, human epidermal growth receptor 2;
GIST, gastrointestinal stromal tumors; ALL, acute lymphocytic leukemia; NSCLC, non-small cell lung cancer; TPMT, thiopurine S-methyltransferase.phase II study comparing a new therapy in selected cases
and controls. The same genomics trials could support several
nested phase II studies testing different agents in patients with
different mutations. However, the frequency of mutated cancer
genes is often less than 10%, and there will be a need to know
the influence of the tissue of origin on outcome. Thus, the sample
size requirement for genomics trials may be larger by at
least one order of magnitude if there is interest in assessing
treatment effect across and within patients with different
cancer histologies that share the same mutations. Although the
number of patients profiled may be greater, the numbers of
patients per treatment arm may be smaller, as the magnitude
of treatment effect should be greater to justify this complex
approach. To achieve large patient numbers, genomics trials
need to recruit patients at multiple centers and, ultimately,
leverage several large multi-institutional trial networks. It is also
likely that, in the future, the scientific community will want to
synthesize data from multiple studies performed across the
globe. This will be enabled not only by instituting appropriate
data sharing policies (see below), but also by using similar
standard operating procedures (SOPs) for sample collection,
processing, analyses, mutation calling, and data collection and
management as much as possible. The net outcome of the
approach will be a new system of cancer classification that will
include genomic factors that make a difference in patient prog-
nosis and treatment.
Efficient workflows are required that incorporate all steps:
initial invitations to participate, consent, sample collection,
genomic analyses, validation of actionable mutations, expert
deliberations, reporting to clinicians, intervention(s) including
access to appropriate therapies, and follow-up (Figure 3). The
addition of complex genetic or genomic testing and interpreta-
tion to clinical trials imposes some time-consuming activities
that could delay the start of therapies. This is particularly trueat this time, as most high-throughput genomic technologies
require weeks and/or months for data generation and analysis.
One way to minimize the potential impact on genomic testing
to create a delay in treatment initiation is to sequence patient
tumors early in the management of their disease—for example,
at the time when metastatic disease is diagnosed and patients
begin their first-line standard of care regimen—as the genomic
information will inform subsequent choices of therapies. The
caveat is, of course, that, over time and with each treatment,
new mutations can be acquired. An alternative to early genomic
testing is to sequence at the time of progression when a change
in therapy is considered. To achieve a turnaround time of less
than 3 weeks (a threshold suggested by clinical trials leaders),
the choice of sequencing technologies and streamlining of
data analysis steps are important.
Patient Recruitment and Informed Consent
Participation in genomics trials requires that prospective
patients be informed of genomic testing and the potential of
future therapies based on genomics results. Whereas the latter
can be administered after genomics results are known and the
informed consent document can be customized according to
the specific intervention being considered, all participants
need to be aware that extensive genomic information will be
generated and that, in addition to generating data regarding
‘‘actionable’’ mutations that may modify treatment decisions,
there may be ‘‘incidental findings,’’ such as germline mutations
associated with risk to other diseases (i.e., long QT syndrome).
Furthermore, germline mutation data could also provide risk
information relevant to family members (i.e., mutations in breast
cancer type 1 susceptibility [BRCA1] or cystic fibrosis genes).
The issue of returning such data to research participants and
patients is currently a controversial topic in bioethics (McGuire
et al., 2008). There is a clear need for experts and stakeholdersCell 148, February 3, 2012 ª2012 Elsevier Inc. 411
Figure 2. Mutation Frequencies in Common Cancers
Selected mutations are those found on Snapshop and OncoCarta panels. The mutation data were obtained from the Sanger Institute Catalogue of Somatic
Mutations in Cancer website at http://www.sanger.ac.uk/cosmic, COSMIC v54 Release (Forbes et al., 2011).to develop a framework that addresses ethical and legal obliga-
tions to inform subjects and family members. In addition, this
framework should consider the preferences and concerns of
research subjects and family members to receive information
on germline variants of risk of cancer and other diseases.
In addition to the ‘‘risks’’ of identifying germline or somatic
mutations that may affect patients or family members, patients
should be aware of the extent that data will be shared and of
the risks andpotential consequences of breach of confidentiality.
To support data sharing across participating networks and412 Cell 148, February 3, 2012 ª2012 Elsevier Inc.ideally across the scientific community (described later), the
consent process should notify participants that data will be
made accessible to national and international researchers under
robustmechanisms to protect confidentiality of participants (Tor-
onto International Data Release Workshop Authors et al., 2009).
Tissue Requirements: Quantity, Quality, Processing,
and Timing
Any framework for clinical decision making on the basis of
somatic genomic alterations requires timely access to tumor
Figure 3. The Genetic Basis for Cancer Treatment
The key steps for the application and evaluation of clinical genomics for cancer treatment include the following. The recruitment of patients and acquisition of
relevant clinical information. Sample collection and analyses for cancer genes. Interpretation of results of genomic analysis based on known functional and
clinical significance of mutation. Provision of information to clinicians and patients for management. Clinical trials of novel treatments offered to cancer patients
who are unlikely to benefit from standard of care and thus have a relatively poor prognosis and/or are more likely to benefit from a novel therapy due to the
presence of tumor genetic abnormalities that predict sensitivity, lack of resistance, or toxicity to a treatment. Assessment of outcomes and sharing of results
across cancer networks to accelerate clinical cancer genomic knowledge.tissue for high-throughputmolecular profiling that is readily avail-
able, of sufficient quality and quantity for successful analysis,
and obtained at a time that the generated mutation profile
remains relevant for the potential available treatments (Dias-
Santagata et al., 2010; MacConaill et al., 2009). Most cancer
patients have archival tissue available for molecular profiling
from either their primary tumor and/or metastasis obtained
from diagnostic biopsy or surgical excision. Local regulations
dictate the minimum time period that hospital pathology depart-
ments must retain archival tumor tissue for the benefit of the
medical care of the patient. In North America, most hospitals
collect and archive tumor specimens as formalin-fixed,
paraffin-embedded (FFPE) blocks to optimize histological
assessment. Although collected on all patients, the diagnostic
samples may or may not be representative of the mutations
that subsequently arise in metastases or as a consequence of
treatment. In addition, DNA and RNA preservation in FFPE tissue
is challenging, as formalin fixation causes crosslinking and
degradation into smaller fragments (Wang et al., 2009). Snap
freezing tumor tissues in liquid nitrogen is the optimal method
of nucleic acid preservation; however, this is not routinely per-
formed outside of select European cancer centers. FFPE does
provide preservation of histological features that allows for
pathological review of hematoxylin and eosin stained slides to
assess tumor cellularity and to mark the regions of tumor for
macrodissection to isolate regions of nonnecrotic tumor from
surrounding stroma.
Quantity and quality of tumor DNA are key sample consider-
ations. Unfortunately, key parameters of tumor cellularity and
optimal quantity of DNA remain unknown. Some authors sug-
gest > 70% tumor cellularity with < 10% necrotic tumor tissue
as guidelines (MacConaill et al., 2009), although less stringent
thresholds may be employed if there is more tumor tissue avail-
able for macrodissection and DNA extraction or a more limited
panel of gene mutation will be assayed. The minimum tumortissue requirement and optimal method of DNA extraction
remain unknown. As few as four 5 micron sections to isolate
15 ng or less of genomic DNA has been described as the require-
ment for successful sequencing using a customized multiplex
colorectal cancer mutation (Colocarta) panel derived from the
Oncocarta v1.0 platform (Sequenom, San Diego, CA) (Fumagalli
et al., 2010). Increased genomic coverage requires greater quan-
tities of tumor DNA. The Oncocarta v1.0 and OncoMap panels,
which include, respectively, 238 mutations in 19 oncogenes
and 400 mutations in 33 oncogenes and tumor suppressors,
recommend at least 500 ng of DNA (MacConaill et al., 2009;
Thomas et al., 2007). There will always be a direct relationship
between the extent of genetic testing and the quantity of DNA
required; however, methods to allow expanded and deeper
genomic sequencing, likely to be the mainstay technologies in
the future for clinical laboratory testing, using small quantities
of DNA from tumor, circulating tumor cells, or DNA would greatly
enhance the successful evaluation of genomic testing in cancer
management.
An unresolved issue is whether archival tissue from the
primary tumor or a fresh biopsy of a metastatic lesion should
be profiled for treatment selection for patients with advanced
refractory disease. It is well recognized that cancers are genomi-
cally unstable and new mutations arise during the process of
metastasis to distant sites, and/or treatment-resistant clones
emerge over time (Campbell et al., 2010; Jones et al., 2010;
Lee et al., 2010; Shah et al., 2009). Although metastatic tumor
biopsies are increasingly acceptable to patients and their physi-
cians if they may inform treatment decision making (Agulnik
et al., 2007), it is not feasible in the current clinical practice envi-
ronment to perform a metastatic tumor biopsy at the time of
treatment resistance in all patients with advanced cancer, and
at each point, a new treatment may be considered. Clonal evolu-
tionmay differ acrossmetastatic sites within an individual patient
(Yachida et al., 2010), suggesting that genomic profiling ofCell 148, February 3, 2012 ª2012 Elsevier Inc. 413
biopsy material from a single metastatic lesion may not be suffi-
cient to completely capture the genomic diversity of advanced
solid cancers.
Nevertheless, available data suggest that individual mutations
may be highly concordant between primary and metastatic sites
and that mutations identified in primary tumors predict benefit to
certain drugs in patients with metastatic disease. For instance,
concordance of KRAS mutations in colorectal primary cancers
and metastases was 96% in two published series (Knijn et al.,
2011; Santini et al., 2008). In non-small cell lung cancer, one
report of a small cohort of 25 cases demonstrated concordance
rates for EGFR and KRAS mutations of 76% (Kalikaki et al.,
2008). Furthermore, the effectiveness of currently available tar-
geted treatments for advanced cancer patients such as gefitinib
or erlotinib for EGFR-mutated lung cancer or trastuzumab for
HER2-amplified breast cancer has largely been demonstrated
from trials that have identified genetic mutations in archived
diagnostic samples rather than new biopsies from metastatic
lesions (Mok et al., 2009; Slamon et al., 2001). In contrast to
high concordance seen for KRAS and EGFRmutations, a recent
study in breast cancer reported discordant PIK3CAmutations in
32% of 103 cases (Dupont Jensen et al., 2011), indicating that
concordance may be mutation and/or tissue-type specific and
may be influenced by prior therapy. At this time, whether to
use archived diagnostic samples versus samples obtained at
the time a new treatment is indicated is driven by convenience,
costs, and standard practices rather than by data. Additional
studies are needed to address the feasibility of biopsying of
metastatic lesions for genomic profiling and whether treatment
decisions based on this approach lead to improved outcomes
compared with genomic profiling of archival samples of the cor-
responding primary tumor. In the current environment, serial bio-
psying of patients is not scalable to large clinical trials or current
clinical practice environments. However, this important question
can and should be addressed through a coordinated effort of
committed investigators and academic cancer research centers.
Genomic Technologies and Data Management
At all stages of development and adoption, companion diagnos-
tics used to identify somaticmutations to inform real-time clinical
decisions need to meet clinical workflow speed requirements
and high levels of test accuracy to not only detect mutant alleles,
but also provide quantitative measure of their abundance.
So-called ‘‘second-generation’’ deep-sequencing instruments
(Natrajan and Reis-Filho, 2011; Wong et al., 2011) currently
used by cancer genome centers to sequence entire genomes,
exomes, transcriptomes, and methylomes often require weeks
for sample template preparation, sequence generation, and
data analyses. Generating and assembling the massive number
of relatively short sequence reads into usable data that specify
genes and mutations remains complex, which partly explains
why this generation of instruments is mostly used in research
facilities with sophisticated databases and highly qualified and
diversified scientific staff. Because these technologies have
had minimal use in diagnostic settings, additional validation of
potential candidate mutations is required using clinical-grade
sequencing assays in certified diagnostic laboratories. The addi-
tion of extensive genomic sequencing and follow-up mutation414 Cell 148, February 3, 2012 ª2012 Elsevier Inc.validation introduces significant stress to the clinical workflow
(Figure 3). The advent of ‘‘third-generation’’ sequencers such
as Pacific Biosciences PacBio RS and Life Technologies’ Ion
Torrent PGM provides increased speed of sequencing due to
their use of sensors that detect nucleotides as they are added
to DNA molecules in synthesis, although parallelization and
machine throughput currently is much lower than with second-
generation technologies (Eid et al., 2009; Korlach et al., 2010;
Rothberg et al., 2011).
In contrast to germline DNA mutations, which represent 50%
or 100% of alleles in heterozygous or homozygous individuals,
respectively, clinically relevant somatic mutations may only be
present in a small percentage of cells and thus represent less
than 5% of sequence reads, either as a result of high percent-
ages of nontumor cells in biospecimens or because some muta-
tions are only present in a subpopulation of tumor cells. To
achieve this needed sensitivity, protocols can be adapted to
obtain high depth (i.e., to generate many overlapping sequence
reads such that every nucleotide is detected multiple times).
Although the typical depth requirement for normal diploid
genomes is usually 20–303, tumor coverage requirements
may need to exceed 1003 to detect clinically relevant somatic
mutations. Important factors for determining depth include the
relative proportions of tumor versus nontumor cells in the sample
extracted for DNA analyses (which can be quite low, for example,
in pancreatic cancer due to high stromal cell content) and tumor
heterogeneity. The latter reflects the mosaic nature of tumors,
whereby multiple subclones diverge in their mutation load
(Figure 1), leading to different proportions of mutant alleles in
the same tumor. The clinical implications of low-abundance
mutations remain unclear.
Capturing sequence information on all nucleotides in
genomes, exomes, or large sets of target genes is challenging
using all current technologies, and the extent of cancer genome
sequence that is needed to inform clinical decisions is debat-
able. There is a small subset of genes that is currently deemed
to be actionable because mutations in these genes already
have diagnostic, prognostic, or predictive implications. Poten-
tially actionable cancer genes should be sequenced in their
entirety. Published coverage estimates for whole-genome and
exome datasets are below 90% (Cancer Genome Atlas
Research Network, 2011), which is inadequate for genes associ-
ated with actionable mutations. Near complete coverage of all
protein-coding bases in important genes can usually be
achieved using polymerase chain reaction (PCR)-based strate-
gies and optimized through trial and error. However, PCR-based
approaches consume relatively more tumor DNA and do not
scale well. In addition, there are thousands of genes that are
known to harbor somatic mutations (see ICGC database).
Though the consequence of most of these mutations is
unknown, it would be useful to prospectively archive all mutation
data in databases that can be shared among cancer organiza-
tions to accelerate the expansion of knowledge regarding clinical
and functional significance of these new mutations. The cost of
sequencing a few hundred genes, exomes, and whole genomes
has and will continue to decrease, with high-throughput labora-
tories currently achieving costs in the $1,000–$2,000 range for
large gene panels as well as exomes when using pooling
strategies (Kozarewa and Turner, 2011). Whole-genome
sequencing is approximately five to ten times more expensive;
given the complexity in their analyses and that most of the clin-
ically interpretable mutations are confined to protein-coding
genes, whole-genome data sets will likely not become routine
studies to be conducted in clinical trials and patient manage-
ment in the next decade. The trade-offs between rapidity of anal-
yses, depth, coverage, cost, and acquisition of new information
on somatic mutations will continue to change in lockstep with
continued improvements in technologies.
Sequencing and other genomic technologies used to detect
somatic mutations are data intensive. The management and
delivery of clinically useful and easily interpretable information
to healthcare providers will need to address several issues,
including data standards, integration and linkages with clinical
and laboratory data and other external data warehouses, and
data security. Some of these issues are generic; for example,
the rapid increase in genomic data generation rate exceeds
the corresponding growth rates in data storage technologies,
network bandwidth, or processing speeds. Robust data pipe-
lines are needed to track data associated with the sequence
information, including instruments, protocols, mutation calling
software, quality metrics, etc. Resolving privacy concerns
around integrating clinical sequence data sets with electronic
medical records requires further efforts.
Informatics challenges related to cancer sequencing arise as
a result of tumor heterogeneity and interpretation of mutation
data. All bases (with or without variants) need to be tracked in
regard to depth, coverage, and base-calling method and confi-
dence score. Because sequence data is ideally generated in
tumor and matched normal samples, parallel data capture and
analysis is needed to classify variants as germline and somatic.
Germline variants can also be screened electronically via poly-
morphism databases such as dbSNP (http://www.ncbi.nlm.nih.
gov/projects/SNP/). Interpreting the clinical significance of
somatic mutations is challenging unless the mutation has previ-
ously been shown to be recurrent and actionable. Rapid access
to curated information on cancer mutations and genes is the
logical first step in this process, as a match with a previously
characterized mutation that is known to predict response to
a targeted therapy is the simplest scenario. Informatics systems
are thus needed to query mutation and cancer gene databases
(such as COSMIC and the NCI Gene Index) and large-scale
data sets generated by The Cancer Genome Atlas (Cancer
Genome Atlas Research Network, 2011) and the ICGC, as well
as the literature to determine what is known about identified
variants. Novel somatic mutations require careful interpretation
that relies on informatics systems that provide information on
the identity of the gene, the functional domain, and the extent
of evolutionary conservation of the affected amino acid.
Software such as SIFT (sorting intolerant from tolerant) (Ng
and Henikoff, 2003) can be used to predict whether an amino
acid substitution affects protein function. Though each
clinical study or cancer center may benefit from storing novel
mutations in its local databases to inform subsequent cases
with similar mutations, many mutations will be too rare to recur
in the same organization, which argues for the establishment
of international databases with mutation, function, patientdemographic, treatment, and outcome data to ensure robust
statistical analyses.
Reporting Data to Clinicians and Patients
Current cancer treatment decisions are informed by knowledge
of a limited number of disease-modifying genes. As the cost of
genome sequencing technologies rapidly declines, it is conceiv-
able that oncologists will have knowledge of an individual
patient’s complete cancer genome in the near future. The
ultimate goal of such comprehensive profiling is to benefit the
individual patient being profiled and, for mutations in germline,
family members. However, for the foreseeable future, the ability
to generate genomic data will supersede the capacity to deci-
pher patterns across complex data sets, draw inferences from
prior experiences, and make informed treatment recommenda-
tions that will benefit the profiled individual patient. Novel tools
to integrate genomic information with traditional clinical and
pathological data in an iterative manner are needed, as are tools
that present complex results to clinicians and patients in under-
standable formats.
Given the complexity of the data, the high number of somatic
mutations that can be detected using large-scale sequencing,
and the many unique situations that will be encountered, there
is a place for establishing expert panels to review the mutation
data, deliberate clinical significance, and offer a multidisciplinary
perspective regarding the consequences of mutation profiles
observed in patients. Multidisciplinary representation allows for
input from experts having different training and background,
including genome scientists, clinicians, ethicists, clinical geneti-
cists, and genetic counselors to provide balanced interpreta-
tions of the potential functional and clinical significance of
mutations in the foreseeable future when information from
diverse sources will rapidly evolve. Expert panel reports to clini-
cians should include the rationale for decisions, the degree of
consensus, and the level of evidence supporting the decision.
Clinical significance should be based on publications reporting
on prognostic or predictive role and whether there are clinical
trials of targeted agents for the protein product of the mutation,
the gene, or pathway. This approach is scalable if it leverages ex-
isting and emerging databases and informatics tools that
generate draft physician reports that can be reviewed and modi-
fied by the expert panel as new information arises. Cursory
review will be needed for frequent actionable mutations, and
more time will be devoted to deal with novel mutations of
possible significance and incidental findings.
The content and format of reports to clinicians are important
considerations. Data reports to clinicians must be understand-
able. Critical pieces of clinical and diagnostic information need
to be prioritized according to their clinical utility and level of
validation. There is a need for easily accessible smart user inter-
faces that provide the support for clinical decisions. These need
to be structured around best practices and tailored to the level of
expertise of the decision maker.
Monitoring and Evaluating the Utility
of Clinical Genomics
It will be critically important to evaluate the utility of genomic
results. For the foreseeable future, genomic sequencing will beCell 148, February 3, 2012 ª2012 Elsevier Inc. 415
Figure 4. Model for Sharing Cancer Genome Data Sets from
Registries and Clinical Trials with Clinicians, Researchers, Regula-
tors, and Policymakers
Novel tools and data repositories are needed to integrate genomic information
with traditional clinical and pathological data and to present complex results to
clinicians and patients in understandable formats. Genomic clinical trials and
registries provide patient demographics, germline and somatic variants,
treatment, and outcomes. Informatics systems query mutation and cancer
gene databases and curated literature to determine what is known about
identified variants. Interpretation of novel somatic mutations may be based on
information on the identity of the gene and the functional domain and extent of
evolutionary conservation of the affected amino acid. Data reports to clinicians
include clinical and diagnostic information on the gene(s) and mutation(s)
according to their clinical utility and level of validation.largely a research approach, and its valuemust be demonstrated
prior to its broad adoption. The genomic information should
be not only understood, but also used by clinicians to inform
their discussions with patients and to modify treatment
recommendation. Such treatment recommendations should
result in improved clinical outcomes at affordable costs. Thus,
genomic clinical trials should ascertain whether the genomic
analyses and mutation-based treatment decisions result in
greater survival, improved quality of life, and avoidance of
toxicity.
It is important to highlight that genomic results will include
somatic mutations, identifying (or failing to identify) a druggable
tumor marker, and (where relevant) the receipt of germline
genetic results identifying inherited risk of cancer, of other
diseases, and of drug toxicity. Information on inherited risks of
disease may have minimal impact on a treatment and outcome
of a patient with advanced cancer; however, such information
may be relevant to patients with potentially curable cancer and
to their family members. What information should be
conveyed—how, when, and to whom—are areas that require
additional research to assess preferences of patients, clinicians,
family members, bioethicists, and policy makers.
Data Sharing
Data from these diverse inputs, linked to information on treat-
ment selection and response, should be broadly leveraged
across research centers to generalize knowledge and increase
the likelihood that genomic profiling will benefit individual
patients in the future (Figure 4). This will require some degree
of altruism among patients to make their personal genomic
and medical information publicly available and a spirit of collab-
oration between researchers to share their data prior to publica-
tion (Mousses et al., 2008; Toronto International Data Release
Workshop Authors et al., 2009). Balancing timely access to
data with protection of sensitive personal health information of
patients and their families is challenging. Four core bioethical
principles have been established by the International Cancer
Genome Consortium (ICGC) to guide data sharing: (1) participa-
tion of individual patients is voluntary; (2) a patient’s care will not
be affected by his/her decision regarding participation; (3)
samples and data collected will be used for cancer research,
which may include whole-genome sequencing; and (4) data
generated will be made accessible to researchers through either
an open or controlled access database under terms and condi-
tions that will maximize participant confidentiality (Hudson
et al., 2010).
Implications for Drug Development
Advances in the understanding of specific somatic mutations or
amplifications and incorporation of single gene tests have had
demonstrable impact on drug development and cancer treat-
ment. The characterization of actionable mutations has already
allowed: (1) selection of subsets of patients for clinical trial partic-
ipation and ultimately for marketing authorization based on
greater treatment benefit (i.e., trastuzumab for HER2 breast
cancer) ; (2) restriction of labeled indications for targeted agents
to avoid treating patients that do not benefit (i.e., lack of efficacy
of EGFR antibodies for colorectal cancer patients with KRAS416 Cell 148, February 3, 2012 ª2012 Elsevier Inc.mutations); and (3) prediction of toxicity risk (i.e., neutropenia
and diarrhea associated with irinotecan in patients for UGT
1A1*28 homozygosity). Molecular testing will continue to impact
patient eligibility for clinical trials, study design, drug approval,
market utilization, and reimbursement; however, the challenges
to rational and practical utilization of complex genomic data are
still not fully understood. The amount of genomic information
becoming available is adding a high level of complexity to the
process of drug development. Information technologies to
manage extensive and diverse biological, chemical, and clinical
data sets and computational methods to identify the most perti-
nent information are essential to guide the development of new
drugs and establish priorities to generate scientific hypotheses
that warrant clinical testing. Clinical development plans for new
agents should aim at documenting major and unequivocal treat-
ment benefit validating the hypothesis.
To date, pilot trials of molecular profiling have focused on
patients with advanced disease to provide a molecular-based
rationale for enrollment of cancer patients in phase I/II clinical
trials and have used exploratory methodologies (Tsimberidou
et al., ASCO, abstract; Von Hoff et al., 2010). The next wave of
trials incorporating tumor DNA sequencing data should establish
that genomic testing is associated with improvements in drug
development processes that ultimately improve patient manage-
ment and provide clinical benefit. Efficient clinical trial designs
are needed to discriminate new agents and/or combination
strategies that warrant further development in patients selected
by genomic testing rather than solely by histological characteris-
tics. Efficiencies in clinical trial conduct are gained by identifying
patients who are unlikely to benefit from currently available treat-
ment and thus have a relatively poor outcome and/or are more
likely to benefit from the investigational agent due to the pres-
ence of tumor genetic abnormalities that confer drug sensitivity.
In either of these situations, fewer numbers of patients are
required to demonstrate an improved treatment effect. This
approach requires the discipline to quickly discontinue develop-
ment when a sufficient signal of activity is not detected in the trial
population thought most likely to benefit from a new treatment or
if such a subgroup cannot be identified. Definitive clinical trials
leading to drug approval should be based on strong scientific
hypotheses and robust signals of activity and should aim to
show efficacy and safety in selected populations based on
complex genomic testing. This will have a major impact on the
drug approval process and will modify marketing expectations
for new agents at least at the time of initial approval. This is,
however, probably the only viable and sustainable approach to
allow the rapid translation of the new genomic advances to the
cancer patients.
Obviously, there are costs to incorporating genomic
sequencing analyses in cancer therapeutic trials. The informa-
tion gained from broad and deep assessments of the cancer
genomemay be greater than needed for a clinical trial evaluating
the safety and activity of an agent of interest to achieve trial
specific objectives. For a given therapeutic agent, the numbers
of genes and associated mutations known to be relevant to the
disease, drug target, and pathway may be relatively limited.
Financial constraints and ethical concerns of administering
agents to patients that may be inactive may also limit the ability
to screen large numbers of patients and enroll them on an
investigational drug trial to determine activity in rare genetic
subgroups. Given the current costs of exome sequencing, aninitial strategy is to ensure coverage of specific genes relevant
to the drug/target, to expand to the top few hundreds of genes
of possible clinical and biological interest, and then, as costs
fall further, to include other emerging genes of interest. As the
information gained from broad molecular screening is of value
beyond the industry sponsors, there should be a willingness
among public agencies, health insurers, philanthropy, and
industry to fund these activities, with the proviso that the infor-
mation gained will be made publicly available.
Implications for Regulatory Bodies
In many jurisdictions, regulatory authorities have adapted their
drug development guidelines, approval decisions, and pharma-
covigilance processes to incorporate the knowledge of specific
gene alterations in individual patients. A recent review of the
approval of 33 new oncology agents approved by the CHMP in
Europe between 2000 and 2008 noted that pharmacogenetic
biomarkers were mentioned in nine cases (EMEA Committee
for Medicinal Products, 2008). Of interest, genetic testing was
associated with prescription restriction of the new agent to
a subset of patients expressing the biomarker. In addition,
many of the regulatory decisions were based on the utilization
of nonapproved tests and, in many cases, on retrospective anal-
yses of subsets of patients enrolled in large phase III trials con-
ducted in nonselected patient populations. This illustrates that,
in the early days of the incorporation of genomic testing in
oncology drug development, regulatory authorities had to be
reactive to a rapidly moving field.
Several new guidance documents have been issued or are in
development to inform the design of clinical studies incorpo-
rating genetic biomarkers and the development of companion
diagnostic tests (FDA, 2005). An example of drug and
companion diagnostic codevelopment paradigm is the recent
approval of vemurafenib for patients with advanced melanoma
harboring the BRAF V600 mutation. This represents the first
FDA approval of a drug and a companion diagnostic mutation
test that stipulates within the package insert the use of the
approved test to determine patient eligibility for treatment.
However, institutions may prefer to perform mutation analyses
using more extensive profiling technologies in their own Clinical
Laboratory Improvement Amendments (CLIA) facilities. Indi-
vidual tests for single or limited numbers ofmutations are unlikely
to be efficient or cost effective for cancer patients or for drug
development. Genomic profiling will generate more extensive
data that could impact patient management to a greater extent
than very selective tests approved by regulatory agencies. In
the case of BRAF, the approved test only documents the pres-
ence of a single point mutation (V600E); however, assessing
other BRAF mutations (i.e., V600K and V600D) and mutations
in other genesmay be relevant to understanding treatment resis-
tance and could ultimately help patients get access to second-
generation inhibitors of different BRAF variants or other relevant
targets. There is a need for collaboration among regulatory
agencies, industry, and academics at the forefront of genomic
technology to develop new approaches for comprehensive
genomic testing in the drug and test approval processes.
In addition to developing new approaches for genomic
testing that will be not only acceptable to regulatory agencies,Cell 148, February 3, 2012 ª2012 Elsevier Inc. 417
but also reflective of the constant scientific progress, other key
regulatory questions related to the evidence of safety and effi-
cacy for drug and test approval need to be addressed. For
example, in highly selected patient populations identified by
genomics testing, are randomized trials needed for initial
approval of a new target therapy, or should the concept of ‘‘tar-
geted approval’’ be considered based on striking results from
open label phase II studies (Chabner, 2011; FDA, 2011)?
What is the size of the safety database that will be required
for initial approval, knowing that genomic-based therapy will
lead to relatively small patient subsets? Generating the large
safety data set in accordance with regulatory guidelines will
become more challenging prior to approval, and the solution
may be the adoption of a risk management program in highly
selected populations after a product has been approved for
marketing. Finally, because tumor growth is usually driven by
complex genomic alterations that cannot be controlled by
inhibiting a single pathway, how should combinations of inves-
tigational agents be developed to document activity and safety
as required by regulatory agencies? The FDA draft guidance on
the development of investigational drug combinations is a first
step to accelerating the early clinical testing of novel targeted
agents (FDA, 2010). It is clear that regulatory authorities are
adapting and providing guidance on issues associated with
genomic testing and drug and diagnostic approvals. However,
further dialog is needed to ensure an appropriate and dynamic
regulatory framework as technological and scientific advances
in cancer genomics and its role in drug development continue
to evolve.
Implications for Patients, Healthcare Providers,
and Payers
The implications of personalized cancer medicine are complex
and can be viewed from the perspectives of the patient, the
healthcare provider, and the society. From the cancer patient’s
perspective, the prospect of receiving specific targeted agents
that match ‘‘driver’’ mutations offers an attractive therapeutic
strategy even though toxicity due to off-target effects may
remain relevant. Until molecular profiling becomes a standard
of clinical care, there are many challenges for the healthcare
provider, such as the access to CLIA-certified laboratories that
can perform validated genomic evaluations, the assurance of
timely turnaround of results to minimize treatment delay, and
the responsibility of finding appropriate treatment for patients
based on the returned results. There will be an expanded need
for clinicians knowledgeable in cancer genetics and the interpre-
tation of genomic results and for clinical geneticists to work
alongside oncologists in multidisciplinary clinics to advise
patients and familymembers on inheritable risks. This will require
new curricula, training, and facile knowledge transfer and
addressing critical shortages of geneticists and counselors
(Cooksey et al., 2005; Cooksey et al., 2006). From the societal
view point, the economic balance of personalized cancer medi-
cine must take into consideration the benefits derived from the
cost savings of avoiding empiric prescription of expensive
medicines versus the expenditures of training personnel with
appropriate expertise, setting up certified laboratories with close
monitoring of quality control, and high-throughput screening.418 Cell 148, February 3, 2012 ª2012 Elsevier Inc.Conclusions
The recent advances in DNA sequencing allow for the character-
ization of a large number of genes and, ultimately, of the entire
cancer genome in a timeframe that is compatible with treatment
decisions for the patient. This creates opportunities for the
development of new agents but also results in challenges that
will only be solved if scientists, clinical investigators, pharmaceu-
tical companies, regulatory agencies, and third-party payers
collaborate closely. A rigorous approach to developing
a complete clinical workflow in which every component of the
process is optimized prior to scale-up is essential.
Genomic analyses and results need to be accessible to guide
management and clinical trial decisions throughout a patient’s
disease course. This means that the information should be avail-
able irrespective of the party who covered the cost of genomic
testing and the initial research study that led to the analyses. It
is essential that access to individual agents and to rational
drug combinations be easier for both investigational agents as
well as marketed drugs. This will require collaboration between
pharmaceutical companies that control access to most of the
new agents available for clinical testing and third-party payers.
Data generated through repetitive genomic studies from indi-
vidual patients at different stages of disease should be made
publicly available to better understand the genomic evolution
according to disease stage and therapeutic intervention. This
information is required to define the clinical setting in which
a therapy will be most effective and to elucidate mechanisms
of therapeutic resistance. Many may argue that such complex
and far reaching collaborations are not attainable; we would
ask ‘‘how can we not?’’ given the overwhelming burden of
cancer and the unprecedented opportunities for advancements
in outcomes for cancer patients.
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